Relapsing Remitting Multiple Sclerosis Clinical Trial
Official title:
A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS). The trial will be conducted on an outpatient basis for minimum treatment duration of 40 weeks.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01945359 -
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design
|
N/A | |
Completed |
NCT01450124 -
Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)
|
Phase 2 | |
Completed |
NCT01456416 -
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
|
Phase 4 | |
Recruiting |
NCT05277740 -
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
|
||
Completed |
NCT03718247 -
Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS
|
||
Active, not recruiting |
NCT03471338 -
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
|
N/A | |
Recruiting |
NCT03004079 -
Clinical Importance of Glucose Regulation in Relapsing MS
|
||
Terminated |
NCT02266121 -
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT01464905 -
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
|
Phase 3 | |
Completed |
NCT01225289 -
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
|
Phase 4 | |
Recruiting |
NCT00242268 -
A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
|
Phase 3 | |
Completed |
NCT00203086 -
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
|
Phase 4 | |
Completed |
NCT00616187 -
Atorvastatin in Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT06083753 -
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
Active, not recruiting |
NCT04602390 -
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
|
Phase 1 | |
Recruiting |
NCT06159712 -
Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04604041 -
Investigation of Subclinical Markers of Multiple Sclerosis
|
||
Terminated |
NCT03536559 -
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT02490982 -
Teriflunomide Observational Effectiveness Study
|
||
Withdrawn |
NCT00939549 -
High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
|
Phase 2 |